PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION
Authors:
- Łukasz DeskaŁDŁukasz Deska
- Cezary KosmeckiCKCezary Kosmecki
- Dawid GłazDGDawid Głaz
- Natalia KamińskaNKNatalia Kamińska
- Wojciech SołtysWSWojciech Sołtys
- Magdalena StolarczykMSMagdalena Stolarczyk
- Maksymilian GłazMGMaksymilian Głaz
- Mateusz StronczyńskiMSMateusz Stronczyński
- Aleksandra Jagura-SukiennikAJAleksandra Jagura-Sukiennik
- Julia WawerskaJWJulia Wawerska
Open Access
- 6 January 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Abstract
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing from systematic reviews, meta-analyses, and clinical trials identified through targeted database searches. Key findings indicate that psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects, with high response and remission rates, often after one or two sessions. Its safety profile is generally favorable, with transient and mild adverse events. Mechanistically, psilocybin primarily acts on serotonin 5-HT2A receptors, modulating brain networks and enhancing neuroplasticity. However, significant challenges exist in terms of high costs, limited accessibility due to the intensive therapeutic model, and regulatory hurdles. In conclusion, psilocybin-assisted therapy offers a promising alternative for depression, particularly where standard treatments fail, by providing rapid and durable symptom reduction through unique neurobiological pathways. Future research should focus on optimizing treatment protocols, exploring long-term outcomes, identifying predictors of response, and addressing systemic barriers to accessibility and cost-effectiveness to facilitate its integration into broader mental healthcare.Keywords
This publication has 51 references indexed in Scilit:
- Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialeClinicalMedicine, 2024
- Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depressionPsychopharmacology, 2024
- Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus StatementJAMA Network Open, 2024
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic propertiesPsychopharmacology, 2024
- Acute Adverse Effects of Therapeutic Doses of PsilocybinJAMA Network Open, 2024
- False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in MarylandJAMA Network Open, 2023
- Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studiesEuropean Neuropsychopharmacology, 2023
- Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trialeClinicalMedicine, 2022
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-upPsychopharmacology, 2017